HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
WST
West Pharmaceutical Services, Inc.
WST's fundamentals are strong: its operating margin rose 3 points to 23% and revenue grew 13%. At 46x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
WST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
WST's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
WST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $314 | -24% |
| Forward | 41x | $411 | — |
| Current | 46x | $411 | — |
| Fair | 47x | $417 | +1.3% |
| Expensive | 61x | $544 | +32% |
Historical ranges are pointers, not guarantees.
WST's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 41x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
WST Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
WST has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
WST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.04 | +13% |
| Q3 2026 | $8.91 | +32% |
| Q2 2026 | $7.81 | +17% |
| Q1 2026 | $7.48 | +17% |
| Q4 2025 | $6.79 | +1.5% |
| Q3 2025 | $6.75 | +0.1% |
| Q2 2025 | $6.68 | -5% |
| Q1 2025 | $6.37 | -16% |
| Q4 2024 | $6.69 | -15% |
WST has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over WST on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
WST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $874.5M | +8.7% |
| Q2 2026 | $872.3M | +14% |
| Q1 2026 | $844.9M | +21% |
| Q4 2025 | $805M | +7.5% |
| Q3 2025 | $804.6M | +7.7% |
| Q2 2025 | $766.5M | +9.2% |
| Q1 2025 | $698M | +0.4% |
| Q4 2024 | $748.8M | +2.3% |
WST's revenue has grown year over year for eight quarters in a row: $875M last quarter, up 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +9.8 points |
| Q2 2026 | 21% | +0.5 points |
| Q1 2026 | 21% | +5.6 points |
| Q4 2025 | 19% | -1.9 points |
| Q3 2025 | 21% | -0.8 points |
| Q2 2025 | 20% | +2.1 points |
| Q1 2025 | 15% | -2.3 points |
| Q4 2024 | 21% | -0.7 points |
WST has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over WST on cash flow, with more consistent year-over-year improvement.
WST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $150.4M | +12% |
| Q2 2026 | $80.8M | -21% |
| Q1 2026 | $47.2M | -19% |
| Q4 2025 | $175M | +105% |
| Q3 2025 | $133.9M | +36% |
| Q2 2025 | $101.9M | +57% |
| Q1 2025 | $58.1M | +111% |
| Q4 2024 | $85.2M | -35% |
WST's free cash flow has been positive every quarter for seven years: $453M over the past year, up 20% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over WST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
WST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -500K shares |
| 1 year | -2.5% | -1.8M shares |
| 3 years | -6% | -4.5M shares |
| 5 years | -6.8% | -5.2M shares |
| Available history | -6.1% | -4.6M shares |
WST has 71M diluted shares, down 2.5% from a year ago, with $685M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $231M |
| Q2 2026 | $156.7M |
| Q1 2026 | $297.6M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $500,000 |
| Q1 2025 | $133.5M |
| Q4 2024 | $54.4M |
WST spent $685M buying back its own shares over the past year, about four times what it spent the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
WST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
WST has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
WST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.6 | Neutral |
| Stochastic | 71.9 | Neutral |
WST's weekly RSI is 70 (neutral) and its Stochastic is 72 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
WST PE vs Healthcare Sector
| Metric | WST | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 47 | 29 | 18 pts above |
WST is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
WST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $387.7 | 6.1% above |
| 20 week MA | $364.5 | 13% above |
| 50 week MA | $312.1 | 32% above |
| 100 week MA | $282.5 | 46% above |
| 200 week MA | $313.1 | 31% above |
WST has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
WST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $150.8 | $283.0 | +88% |
| 2021 | $283.0 | $459.8 | +63% |
| 2022 | $459.8 | $235.1 | -49% |
| 2023 | $235.1 | $352.1 | +50% |
| 2024 | $352.1 | $333.2 | -5.4% |
| 2025 | $333.2 | $274.3 | -18% |
| 2026 YTD | $274.3 | $411.3 | +50% |
WST has the edge over HIMS on returns for 2026, with the stronger performance.